CervoMed completes last patient visit in Phase 2b DLB trial; topline data expected Dec 2024

CervoMed Inc.

Last patient last visit completed in Phase 2b RewinD-LB trial evaluating neflamapimod in early-stage DLB.
96% of patients completed the 16-week double-blind placebo-controlled portion; 98% continued into open-label extension.
DSMB concluded study may proceed without modification after pre-specified safety data review.
Company on track to report topline efficacy and safety data in December 2024.
Late-breaking oral presentations on plasma biomarker data planned at upcoming CTAD conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.